7PA-27281-75930
3 vaccinations
4 coded responses
23 check-ins
4 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 46-50
- ZIP prefix
- 381 / TN
- Registered
- 2021-03-17
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-02-27
Dose 1 — Pfizer-BioNTech
-
2021-03-17
Registered in v-safe
- 2021-03-17
-
2021-03-20
Dose 2 — Pfizer-BioNTech
- 2021-03-20
-
2021-03-21
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-03-24
- 2021-03-25
- 2021-03-26
- 2021-03-29
- 2021-04-10
- 2021-04-26
- 2021-05-03
- 2021-06-21
-
2021-11-09
Dose 3 — Pfizer-BioNTech
-
2021-11-11
Survey response — days 1–6 daily, dose 3MedDRA: Lymphadenopathy — Feeling: Fair · Site: Pain · Fatigue or tirednessFree text: Swollen lymph node in armpit (same side as injection)MedDRA releases: 2024-11 · check-in free text available
-
2021-11-12
Survey response — days 1–6 daily, dose 3MedDRA: Lymphadenopathy — Feeling: Fair · Site: Pain · Fatigue or tirednessFree text: Swollen lymph node in armpit - same side as injection but milder than yesterdayMedDRA releases: 2024-11 · check-in free text available
- 2021-11-14
- 2021-11-15
- 2021-11-16
- 2021-11-23
- 2021-12-02
- 2021-12-09
- 2021-12-23
-
2022-02-08
Survey response — 3 months, dose 3MedDRA: Cough, Fatigue, Respiratory tract congestion, SARS-CoV-2 test positive — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Congestion and cough, tiredness - positive COVID test on January 20thMedDRA releases: 2024-11 · check-in free text available
-
2022-02-08
Report sent to call center — 3 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
-
2022-02-10
Call successfulNot applicable (accidental reporting or does not believe symptoms are related to vaccine)
- 2022-05-12
-
2022-11-09
Survey response — 12 months, dose 3MedDRA: Cough, Nasopharyngitis — Feeling: Fair · Be unable to work or attend schoolFree text: Cold and coughMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-27 | Pfizer-BioNTech | |
| 2 | 2021-03-20 | Pfizer-BioNTech | |
| 3 | 2021-11-09 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-02-08 | Successful 2022-02-10 |
Not applicable (accidental reporting or does not believe symptoms are related to vaccine) |
Free text
Release 10 — days 1–6 daily, dose 3
Systemic reaction (other): Swollen lymph node in armpit (same side as injection)
Systemic reaction (other): Swollen lymph node in armpit - same side as injection but milder than yesterday
Release 11 — 3 months, dose 3
Symptoms: Congestion and cough, tiredness - positive COVID test on January 20th
Release 12 — 12 months, dose 3
Symptoms: Cold and cough
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SD | SARS-CoV-2 test positive | · | · | ✓ |
| SRO | Lymphadenopathy | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release